Protara Therapeutics
TARA
14 hedge funds and large institutions have $2.25M invested in Protara Therapeutics in 2019 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 17 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
0.54% less ownership
Funds ownership: 1.12% → 0.58% (-0.54%)
48% less funds holding
Funds holding: 27 → 14 (-13)
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
76% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 17
89% less capital invested
Capital invested by funds: $19.6M → $2.25M (-$17.3M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$391K |
| 2 |
WS
Wedbush Securities
Los Angeles,
California
|
+$168K |
| 3 |
TSS
Two Sigma Securities
New York
|
+$145K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$45.1K |
| 5 |
RJFSA
Raymond James Financial Services Advisors
St. Petersburg,
Florida
|
+$32.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NLVP
New Leaf Venture Partners
New York
|
-$3.46M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$3.04M |
| 3 |
MAM
MPM Asset Management
Boston,
Massachusetts
|
-$2.23M |
| 4 |
BBA
Baker Bros. Advisors
New York
|
-$678K |
| 5 |
BFM
Boothbay Fund Management
New York
|
-$246K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
EP
26
Elkfork Partners
Portland,
Oregon
| – | -$7K | -72 | Closed |
|
|
GHCM
27
Glen Harbor Capital Management
San Diego,
California
| – | -$5K | -60 | Closed |
|
|
MCIM
28
Meadow Creek Investment Management
Atlanta,
Georgia
| – | -$4K | -47 | Closed |
|
|
FCM
29
Flinton Capital Management
Philadelphia,
Pennsylvania
| – | -$3K | -34 | Closed |
|
30
UBS Group
Zurich,
Switzerland
| – | -$3K | -30 | Closed |
|
TARA Hedge Fund Activity: Q1 2019 in Review
14 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Protara Therapeutics (TARA) for Q1 2019, worth a combined $2.25M — down 89% from $19.6M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of TARA and 4 opened new positions — a net loss of 13 holders — while 1 trimmed existing stakes and 3 added.
The largest buyer was Renaissance Technologies, adding an estimated $391K. The largest seller was New Leaf Venture Partners, exiting entirely with an estimated $3.46M sold.
- 14 institutional investors held Protara Therapeutics (TARA) as of Q1 2019, down from 27 in Q4 2018.
- Funds reported $2.25M of Protara Therapeutics stock for Q1 2019, down 89% quarter-over-quarter.
- 4 funds opened new Protara Therapeutics positions in Q1 2019 and 17 closed out, a net change of -13 holders.
- The largest Protara Therapeutics buyer in Q1 2019 was Renaissance Technologies, an estimated $391K added.
- The largest Protara Therapeutics seller in Q1 2019 was New Leaf Venture Partners, an estimated $3.46M sold.
Based on aggregated 13F filings for Q1 2019.